Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma

DSpace/Manakin Repository

Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma

Citable link to this page

. . . . . .

Title: Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma
Author: Van Steen, Kristel; Kaplan, Feige; Raby, Benjamin Alexander; Su, Jessica Ann Lasky; Tantisira, Kelan; Weiss, Scott Tillman

Note: Order does not necessarily reflect citation order of authors.

Citation: Raby, Benjamin A., Kristel Van Steen, Jessica Lasky-Su, Kelan Tantisira, Feige Kaplan, and Scott T. Weiss. 2009. Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. Respiratory Research 10(1): 67.
Full Text & Related Files:
Abstract: Background: Glucocorticoid function is dependent on efficient translocation of the glucocorticoid receptor (GR) from the cytoplasm to the nucleus of cells. Importin-13 (IPO13) is a nuclear transport receptor that mediates nuclear entry of GR. In airway epithelial cells, inhibition of IPO13 expression prevents nuclear entry of GR and abrogates anti-inflammatory effects of glucocorticoids. Impaired nuclear entry of GR has been documented in steroid-non-responsive asthmatics. We hypothesize that common IPO13 genetic variation influences the anti-inflammatory effects of inhaled corticosteroids for the treatment of asthma, as measured by change in methacholine airway hyperresponsiveness (AHR-PC20). Methods: 10 polymorphisms were evaluated in 654 children with mild-to-moderate asthma participating in the Childhood Asthma Management Program (CAMP), a clinical trial of inhaled anti-inflammatory medications (budesonide and nedocromil). Population-based association tests with repeated measures of PC20 were performed using mixed models and confirmed using family-based tests of association. Results: Among participants randomized to placebo or nedocromil, IPO13 polymorphisms were associated with improved PC20 (i.e. less AHR), with subjects harboring minor alleles demonstrating an average 1.51–2.17 fold increase in mean PC20 at 8-months post-randomization that persisted over four years of observation (p = 0.01–0.005). This improvement was similar to that among children treated with long-term inhaled corticosteroids. There was no additional improvement in PC20 by IPO13 variants among children treated with inhaled corticosteroids. Conclusion: IPO13 variation is associated with improved AHR in asthmatic children. The degree of this improvement is similar to that observed with long-term inhaled corticosteroid treatment, suggesting that IPO13 variation may improve nuclear bioavailability of endogenous glucocorticoids.
Published Version: doi:10.1186/1465-9921-10-67
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724419/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4887102

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters